Evaluation of Overactive Bladder Symptoms in Patients Recovering from Post-Acute COVID-19 Syndrome

Figures & data

Table 1 Demographics of Patients’ Study

	N Patients	Control Group
Patient population	66	40
Age median (range)	59.5 (44–72)	58.8 (46–71)
Female (%)	30 (45.5%)	16 (40%)
Male (%)	36 (54.5%)	24 (60%)
New Onset (%)	44 (66.6%)	No COVID-19
Worsening Symptoms (%)	22 (33.3%)	No COVID-19
BPH (% male population)	16 (44.4%)	8 (33.3%)

Table 2 Primary Outcomes for Symptoms and Quality of Life Scores

	Symptom Score (Mean±SD)	QoL Score (Mean±SD)
New	18.25±2.11	17.74±2.34
Worsening OAB symptoms
Before	10.43±1.52	9.04±1.41
After	17.87±1.89	18.84±1.96
P value	<0.05	<0.05
Gender
Female (total population)	18.09±1.99	18.51±2.23
Male (total population)	17.78±1.87	18.45±2.09
P value	>0.05	>0.05

Table 3 Patients’ Evaluation for Symptoms and Quality of Life Scores in Control Group

Control Group Patients with OAB Symptoms	Symptom Score (Mean) ± SD	QoL Score (Mean) ± SD
Before	12.45 ± 1.23	11.61 ± 1.17
After	12.76 ± 1.37	12.05 ± 1.31
P value	>0.05	>0.05

Abbreviations: SARS-CoV-2, Severe Acute Respiratory Syndrome Coronavirus-2; COVID-19, Coronavirus Disease 2019; PACS, Post-Acute COVID-19 Syndrome; LUTS, Lower Urinary Tract Symptoms; OAB, Overactive Bladder; CAC, COVID-19 Associated Cystitis; MMSE, Mini-Mental State Examination; AUA OAB tool, AUA Urology Care Foundation Overactive Bladder Assessment Tool; QoL, Quality of Life; ACE_2, Angiotensin-Converting Enzyme 2; TSPRSS2, Transmembrane Serine Protease 2.